Drug Profile
Research programme: dipeptidyl peptidase-4 inhibitors - HitGen
Alternative Names: DPP4 inhibitors - HitGenLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator HitGen
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in China (PO)
- 01 Mar 2017 Dipeptidyl peptidase-4 inhibitors - HitGen is available for licensing as of 01 Mar 2017. http://www.hitgen.com/?page_id=7076 (HitGen pipeline, March 2017)
- 01 Mar 2017 Preclinical trials in Type-2 diabetes mellitus in China (PO) before March 2017 (HitGen pipeline, March 2017)